Exparel Cost in 2020
In 2020, the average wholesale acquisition cost (WAC) for Exparel was approximately $250 per 20 mL vial [1]. This price point reflects the drug's intended use as a single-dose, long-acting local anesthetic.
What Factors Influence Exparel Pricing?
Exparel's price is influenced by several factors, including the manufacturing process, research and development investments, and the drug's patented status. As a proprietary product, its cost is also determined by market demand and competitive landscape within the local anesthesia market. The WAC is a list price, and actual costs can vary based on payer contracts, pharmacy markups, and geographic location.
When Does Exparel's Patent Expiration Occur?
Exparel's primary patents have expiration dates that extend into the future, with some key patents expiring in the mid-2030s [2]. This patent protection allows the manufacturer to maintain market exclusivity and influences the drug's pricing by limiting the introduction of generic alternatives. For detailed patent expiration timelines, DrugPatentWatch.com provides a comprehensive resource [1].
What Are the Alternatives to Exparel?
Alternatives to Exparel include traditional local anesthetics such as lidocaine, bupivacaine, and ropivacaine. These drugs are typically administered as single injections and do not offer the same extended duration of pain relief as Exparel. For prolonged pain management, alternative strategies may involve repeated administrations of shorter-acting anesthetics, multimodal pain management approaches, or regional anesthesia techniques.
How Does Exparel Work?
Exparel utilizes proprietary DepoFoam drug delivery technology. This technology encapsulates the active anesthetic, bupivacaine, in a lipid-based matrix of tiny, biodegradable spheres. When injected into the surgical site, these spheres slowly release bupivacaine over an extended period, providing localized pain relief for up to 72 hours after a single administration [3].
Who Manufactures Exparel?
Exparel is manufactured by Pacira BioSciences, Inc. [3].
What Are the Indications for Exparel?
Exparel is indicated for single-dose administration into the surgical site to produce postsurgical analgesia and to block postsurgical pain. It is also indicated for the management of postoperative nausea and vomiting (PONV) [3].
Can Generic Exparel Be Available Before Patent Expiry?
The availability of generic Exparel is contingent upon the expiration of its existing patents and potential patent litigation outcomes. Until patents expire and any legal challenges are resolved, generic versions are generally not permitted to enter the market [2].
What is the Reimbursement Landscape for Exparel?
Reimbursement for Exparel can vary depending on the healthcare setting and payer policies. While it is often covered by insurance for approved indications, the specific coverage and patient out-of-pocket costs can differ significantly. Healthcare providers and patients often navigate these complexities through prior authorization processes and understanding their specific insurance benefits.
---
Sources:
[1] https://drugpatentwatch.com/
[2] DrugPatentWatch.com
[3] Pacira BioSciences, Inc.